Back to top
more

Jasper Therapeutics (JSPR)

(Real Time Quote from BATS)

$22.92 USD

22.92
24,271

-0.10 (-0.43%)

Updated May 20, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Jasper Therapeutics (JSPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know

by Zacks Equity Research

Does Jasper Therapeutics, Inc. (JSPR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going

by Zacks Equity Research

Jasper Therapeutics, Inc. (JSPR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength

by Zacks Equity Research

Jasper Therapeutics, Inc. (JSPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

by Zacks Equity Research

Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

by Zacks Equity Research

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.

CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

by Zacks Equity Research

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

by Zacks Equity Research

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

by Zacks Equity Research

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

by Zacks Equity Research

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.

Viking (VKTX) Announces Clinical Data for Metabolic Disorders

by Zacks Equity Research

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe

by Zacks Equity Research

Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).

Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

by Zacks Equity Research

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

by Zacks Equity Research

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

by Zacks Equity Research

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA

by Zacks Equity Research

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

Here's Why You Should Add CRISPR Stock to Your Portfolio

by Zacks Equity Research

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

Axsome (AXSM) Stock Up 17% in Six Months: Here's Why

by Zacks Equity Research

Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.

Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to Buy

by Zacks Equity Research

Jasper Therapeutics, Inc. (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.